Radotinib

Drug Profile

Radotinib

Alternative Names: IY5511; IY5511HCl; Radotinib hydrochloride; Supect

Latest Information Update: 29 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Il-Yang
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia

Most Recent Events

  • 22 Jul 2017 Efficacy data from a phase III trial in Chronic myeloid leukaemia (Second-line therapy or greater) presented at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 22 Jun 2017 Efficacy and safety data from a long term phase II trial in Chronic myeloid leukaemia (Second line therapy or greater) present by Il-Yang at the 22nd Congress of the European Haematology Association (EHA-2017)
  • 11 Sep 2015 Radotinib is still in phase-III development for Chronic myeloid leukaemia in Indonesia, Philippines, Thailand and South Korea (Newly diagnosed, First-line therapy) and in Thailand (second-line therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top